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Clostridium difficile Associated Disease (CDAD)
Rivka H. Borger
Abstract
Clostridium difficile bacteria (C. difficile) are a spore-forming species of bacteria that lies
dormant in the colon, in the presence of normal intestinal flora. Due to overuse of certain antibiotics,
normal intestinal bacteria may be depleted, and combined with other
possible risk factors, allow C. difficile bacterial spores to develop into
active, infectious, and extremely resistant toxin-producing bacteria. The
toxins cause severe damage and inflammation to the intestinal wall that
can result in gastrointestinal discomfort and severe pseudomembranous
enterocolitis that must be treated with a low-risk C. difficile targeting
defense.
Figure 1 –Endoscopic
view of classic C difficile–
associated
pseudomembranous
colitis (Hull and Beck,
FMC, 2006)

Introduction

Clostridium difficile bacteria (C. difficile) are a spore-forming
species of bacteria that lie dormant in the human colon, in the presence
of normal intestinal flora. It is a commensal bacterium in a minority of the population. Smaller numbers
do not develop into significant disease. (Nation Master Encyclopedia, 2005) Most commonly due to
overuse of certain antibiotics, normal intestinal bacteria may be depleted, and through nutrient
competition, allow C. difficile bacterial spores to develop into active, infectious, and extremely resistant
toxin-producing bacterial overgrowth. The toxins cause severe damage and inflammation to the
intestinal wall resulting in a wide range of disease, but most commonly - severe enterocolitis. (Merck
Manual of Diseases, 2006)
The following discourse will detail the morphology, mechanism of infection, causes, diagnoses,
treatment, and prevention of Clostridium difficile Associated Disease.

Clostridium difficile Bacteria
Clostridium difficile is a Gram-positive anaerobic rod-shaped bacterium (Kunkel, 2006). The
species was named ‘difficile’ because it was initially hard to culture (Schroeder, MD, American Family
Physician, 2005). It belongs to the Clostridiaceae Family and genus Clostridium, which form spores.
They are motile bacteria that are numerous through nature, particularly soil. Clostridium show optimal
growth at human body temperatures, but can exist under stress in the more tolerant spore form.
(Nation Master Encyclopedia, 2005). The spores are resilient and resistant to high temperatures. Early
studies demonstrated that C. difficile could be isolated from the gastrointestinal tracts of most
neonates, identifying it as a commensal organism (Schroeder, 2005). It is found as part of the normal
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intestinal flora, and passed out with the feces of those with C. difficile spores in their intestines. (EMIS
and PIP, 2007)
Clostridium difficile produce at least two exotoxins: an enterotoxin (Toxin A) and a cytotoxin
(Toxin B). They can kill cells by altering the apical membrane permeability of the mucosal cells of the
intestinal wall, and are subsequently responsible for severe inflammation possibly leading to
enterocolitis (Gerding et al, 1995). Another toxin, binary toxin, has been identified without a role in
CDAD infection. (Nation Master Encyclopedia, 2005)
C. difficile can be passed through fecal matter and spores can lie almost anywhere in the
environment.
Clostridium difficile is considered a member of infant intestinal flora as up to 50% of infants
carry asymptomatic C. difficile in their intestinal tracts. It can grow to high numbers with elevated toxin
production with no harmful effects to
infants. (Bongaerts and Lyerly, 1996)
The normal intestinal flora
under typical conditions keep the
spores of C. difficile inactive by
outnumbering them in strength. Upon
depletion of normal flora, the dormant
inactive spores develop into active,
infectious, and resistant bacteria –
replacing the lost bacteria due to
imbalance (Merck Manual, 2006)
More recently, C. difficile
infections are more rampant – severe,
Figure 2 –Scanning electron microscopy of Clostridium
extremely
resistant,
and
easily
difficile bacteria specimen, obtained from human intestine
recurrable. (Kelly and LaMont, 2008).
It is the most frequent etiologic basis
(Wiggs, University of Waikato, 2007)
for healthcare-associated diarrhea and
a common cause of antibioticassociated diarrhea (AAD), accounting for 15-25% of all AAD episodes (Center for Disease Control and
Prevention (CDC), 2004). There have been increasing rates of CDAD-associated mortality, and this can
be due either to elevated risk population or identification of new highly virulent strains of the disease.
(Center for Disease Control and Prevention (CDC), 2005).
Additionally, two studies have proven C. difficile to be the most frequent cause of nosocomial
diarrhea. Multiple studies demonstrate the link between C. difficile and noscomial infection – many
cases arise from contamination of hospital environment (Gerding, et al, 1995).
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Clostridium difficile was first linked to disease in 1978 when it was identified as primary
causative agent of pseudomembranous colitis. It can cause disease ranging from minor gastrointestinal
discomfort
to
severe
enterocolitis, toxic megacolon, or
death.
(Sunenshine
and
McDonald, 2006)

Pathogenesis
Inflammation develops
when environmental spores
ingested infect the patient.
Spores can survive the low pH of
the gastrointestinal tract and
survive well in the anaerobic
environment of the large
intestine,
allowing
for
Figure 3 –
germination. Upon depletion of
Scanning electron microscopy of Clostridium difficile bacteria spreading on
normal intestinal flora, C. difficile
a surface
spores no longer have to
(Dave McCarthy and Annie Cavanagh, School of Pharmacy, University of
compete with other microbes,
London, 2008)
allowing them to thrive to full capacity, growing to large numbers – approximately 108 bacteria per gram
of feces. In the absence of colonic flora depletion, colonization of C. difficile will be asymptomatic and
harmless (Bongaerts and Lyerly, 1997).
Antibiotic overuse is the most common form of intestinal flora depletion. The inactive spore
from of C. difficile, once held in check by nutrient competition, becomes the dominant intestinal species.
It is transformed to its infectious form, producing toxins that inflame and damage the intestinal mucosa.
Inflammation results in hyperleukocytosis, influxing towards the colon. Colitis is variable in
degree, from mild to extremely severe. In pseudomembranous colitis, a more severe form, toxins
destroy the tissue of the intestinal epithelia until the tissue falls off, mixes with leukocytes in pus
discharge; giving the appearance of a white membranous patch on the inner intestinal lining. Some
patients infected with C. difficile do not develop colitis, but are carriers of the disease, able to transmit it
to other high-risk individuals.
Clostridium difficile bacteria’s capacity to form spores allows the organism to persist in various
areas of the environment. Additionally, the spores can be spread through fecal contamination, infecting
at-risk individuals. (EMIS and PIP, 2007) Transfer can occur via the hands of healthcare workers as well.
(Center for Disease Control, 2008). Infection used to be limited to elderly hospitalized individuals but
has grown rampant more recently. (DeNoon, 2006).
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After colonic colonization, C. difficile bacteria carry out metabolic activities similar to other
anaerobic organisms. The bacteria use some monosaccharides (i.e. glucose, fructose, mannitol,
mannose, and xylitol), but not disaccharides (i.e. lactose or sucrose), oligosaccharides, or
polysaccharides (i.e. starch). C. difficile uses substances not found free in nature, such as N-acetylglucosamine and N-acetyl-neuraminic acid, by using extracellular hydrolytic enzymes to degrade
substrates for nutrition. It can then obtain carbohydrates, amino acids, and related nutrients allowing
the bacteria to thrive in the intestine. With the depletion of normal flora, there are more nutrients
available for the bacteria to thrive on. Additionally, when a large amount of resident intestinal bacteria
are destroyed, it allows Clostridium difficile exposure to previously hidden sites of the intestine. They
can be then used for microcolony formation or receptor sites for toxins in toxigenic strains. As the
organism grows, it becomes harder for normal flora to replace it since the bacteria produces inhibitory
metabolic products, such as p-cresol, ammonia, and isocaproic acid – all inhibiting growth of normal
flora, and disturbing intestinal epithelial cell membrane function. (Bongaerts and Lyerly, 1997)
Pathogenic strains of Clostridium difficile cause enterocolitis primarily through the production of
toxin A (enterotoxin) and toxin B (cytotoxin). Both toxins are capable of stimulating proinflammatory
cytokine production implicated in pseudomembranous colitis infection. Toxins act by altering regulation
of cytoskeletal protein, leading to cell rounding and cell death. (Hull and Beck, College of Family
Physicians of Canada, 2004) The toxins cause leukocyte chemotaxis and the upregulations of
inflammatory mediators such as cytokines, producing colonic inflammation. Clinical evidence would be
a significantly elevated white blood cell count, correlating to presence of infection. Focal ulcerations
occur with increasing severity of colitis, and necrotic tissue form a membrane-like material. Thus, it is

Figure 4 – The Potent Effects on Toxin B vs. Toxin A on Intestinal Epithelium
(A)
(B)

Control, treated with buffer alone – no toxins. (B) treated with 32 nM of toxin A for 5 hours. (C) and (D)
treated with 3 nM of toxin B for 5 hours.
Exposure to toxin A shows disruptions of superficial epithelium with crypt epithelium intact. (C) treatment
with toxin B shows disruption of superficial epithelium as well. (D) shows higher magnification of colonic
damage wrought by toxin B.
(Riegler, et al, Journal of Clinical Investigation, 1995)
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called pseudomembranous colitis (Schroeder, 2005).
Animal models show toxin A induction of epithelial desquamation, increased mucosal
permeability leading to increased fluid secretion in the intestine. Toxin B has less enterotoxic effects in
animals with less correlation as a cause of disease in humans, but recent in vitro data based on human
intestinal epithelial cell testing suggests that toxin B is ten times more likely to induce colonic damage
than does toxin A. In this experiment, human intestinal mucosa was exposed to varying amounts of
both Clostridium difficile toxins A and B for five hours and subsequent damage was observed. Significant
damage was observed afterward, both electrophysiologically and morphologically. Both toxins caused
disruption to cellular F-actin and patchy damage and exfoliation was noted on superficial intestinal
epithelium. The difference lay in the potency of individual toxins. While both toxin A and toxin B caused
severe intestinal damage, toxin B disrupted the colon in a minute concentrated amount, while toxin A’s
measurement was significantly greater. This suggests the high potency of toxin B in Clostridium difficile
Associated Diseases. (Riegler et al, 1995)
In a 1999 study hypothesizing how C. difficile – induced alterations in intestinal barrier facilitate
microbial entry to the intestinal mucosa (thus facilitating microbial pathogenic shift within the intestine),
mature enterocytes were deliberately treated with varying concentrations of toxins A and B followed by
an hour incubation with an enteric microorganism such as Escherichia coli. Effects of toxins A and B
were assessed on all aspects of enterocyte function ability. Testing of the effects of toxin A and B on
mature enterocytes in vitro resulted in damage and alterations in enterocyte actin, increased bacterial
adherence and paracellular transmigration, thus correlating that Toxins A and B may facilitate bacterial
adherence and penetration of the intestinal epithelium. (Feltis, et al, 1999)
If the infecting strain is toxigenic, the patient is at risk for disease. There are other factors that
possibly affect its potency such as fimbriae (enabling bacterial adherence) and glycocalyx
(antiphagocytic capsule), both of which are produced in greater numbers in toxigenic strains of C.
difficile. Some highly virulent strains produce elevated protease levels, linked among other clostridial
pathogens to increased virulence. Other extracellular hydrolytic enzymes may play a similar role
(Bongaerts and Lyerly, 1997).
C. difficile bacteria can also have specific antibiotic-resistant genes, targeting specific
antimicrobial agents through unique bacterial physiology and biochemistry. An example of this would
be the ermB gene, encoding a 23S ribosomal methylase that causes resistance to macrolide-lincosamidestreptogrammin (MLS) antibiotics. This marker was noted in several cases of C. difficile after use of
Clindamycin, a lincosamide derivative. (Hull and Beck, 2004).
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Another strain of Clostridium difficile bacteria has been identified relatively recently, named
North American pulsed-field gel electrophoresis type 1 (NAP 1), causing several outbreaks in North
America and Europe. It is resistant to both gatifloxacin and moxifloxacin antibiotics (both of the
fluoroquinolone antibiotic group), unlike other strains previously designated. NAP 1 produces 16 times
greater toxin A and 23 times greater toxin B than other strains do, possibly related to a deletion in a
negative regulatory gene. It also produces a third toxin, binary toxin, whose purpose has not been
deemed significant yet. (Sunenshine and McDonald, 2006). This new strain has become the more
dominant strain, due to the high rate of mutation. It is highly virulent and has raised C. difficile-related
death rates by 35% yearly (DeNoon and Chang, 2008). Additionally, resistance to fluoroquinolone
antibiotics gives the NAP-1 strain with the ability to spread more rapidly among healthcare
environments where those antimicrobial agents are most frequently used. (Center for Disease Control
and Prevention (CDC) 2005)

Causes and Risk Factors
The primary cause of infection is due to
antimicrobial therapy, more prevalent in
certain antibiotic groups.
Antimicrobial agents that target
anaerobic bacteria are potentially more lethal,
possibly because they alter intestinal flora and
microbial ecology. (Gerding et al, 1995)
Almost all antimicrobial agents except
for aminoglycosides are associated with
Clostridium difficile infection (Sunenshine and
(Cleveland Clinic, 2006)
McDonald, Cleveland Clinic Journal of Medicine,
2006). Clindamycin has been identified as a
targeting agent, confirmed by ermB gene isolation, encoding methylase enzyme causing antibiotic
resistance to lancosamides (Clindamycin belonging to that family). (Hull and Beck, College of Family
Physicians of Canada, 2005). Other common high-risk antibiotics are broad spectrum penicillins, second
and third generation cephalosporins, erythromycin, sulfonamides, chloramphenicol, tetracycline, and
fluoroquinolones. Fluoroquinolones in particular were isolated in a cohort study as the predominant
risk factor for CDAD in a specific epidemic in Quebec 2003-4 (Pepin et al, 2005). It is most commonly
due to oral antibiotics but can also occur due to intravenous or intramuscular antibiotics. (Merck
Manual, 2006). Other antimicrobial agents, including antiviral and antifungal drugs increase the risk as
well (Mayo Clinic 2006). Risk more than doubles with greater than three days of antimicrobial therapy.
Figure 5– marked exudates protruding through
mucosal ulcerations

Reduced-risk
(Schroeder, 2005).

antibiotics

include

vancomycin,

metronidazole,

and

antipseudomonals.
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The critical point of infection is right after normal intestinal flora depletion before replenishing
(Bongaerts and Lyerly, 1997).
Other drugs may increase susceptibility as well, such as drugs and conditions that decrease
gastric acidity. Over the counter antacids and proton pump inhibitors such as aciphex, prevacid, and
related drugs would put a patient at higher risk (Merck Manual, 2006). Proton pump inhibitor (PPI)
utilization is associated with upper gastrointestinal tract colonization and altering of intestinal flora.
Decreased gastric acidity is a known risk factor for infectious diarrheal illnesses. Since Clostridium
difficile bacteria thrive on higher gastric pH levels, decreased gastric acidity may also pose a risk factor
for CDAD. This is supported by CDAD cases reported from patients receiving Helicobactor pylori
treatment – combining proton pump inhibitors with antibiotics. A study comparing rate of C. difficile
infection in patients undergoing gastric acid suppressive therapy with those who did not, with PPI usage
increasing the risk significantly. (Dial et al, CMAJ, 2004). Two case-controlled studies conducted over ten
years showed the increase in rate of Clostridium difficile infection due to PPI usage and H2 blockers.
(Dial, et al, JAMA, 2005).
Additional risk factors included use of non-steroidal anti-inflammatory drugs (NSAIDs), such as
ibuprofen. Being methicillin-resistant Staphylococcus aureus positive increases susceptibility in hospital
patients. (Dial, et al, JAMA, 2005).
Exposure to Clostridium difficile can occur through a variety of methods. Transfer of pathogenic
organisms is highly prevalent via the hands of health-care workers and is considered the most likely
mechanism. (Centers for Disease Control and Prevention (CDC) 2007).
Other risk factors include underlying illness, weakened immune system, recent hospitalization,
residency in long-term care facilities, recent surgery – primarily abdominal/gastrointestinal, chronic
colon disease such as inflammatory bowel disease or colon cancer. Additionally, previous infection with
Clostridium difficile increases patient susceptibility to reinfection. (Mayo Clinic, 2006). Highest risk
patients are those with recent immunosuppressive therapy or recent surgical procedures, partly due to
patients’ inability to generate IgG antibody immune response against Clostridium difficile toxin A. IgG
immune response ability does not protect against colonization but can decrease risk of morbidity,
mortality, or recurrence with C. difficile infection (Schroeder, 2005).
Cancer chemotherapy and increased age and severity of underlying illness are other possible risk
factors (Hull and Beck, 2005)

Clinical Manifestations of Enterocolitis
More commonly, patients experience colonization rather than disease. Such patients exhibit no
clinical symptoms even though they would test positive for C. difficile organism and/or toxins. Other
times, patients contract Clostridium difficile-Associated Disease (CDAD) and exhibit clinical symptoms
(Centers for Disease Control and Prevention, 2005).
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Common symptoms for Clostridium difficile infection are watery diarrhea (characterized by at
least three bowel movements daily for more than two days but usually ten or more), abdominal
cramping and tenderness, nausea, loss of appetite, and fever of up to 104 – 105 degrees F. (Centers for
Disease Control and Prevention, 2004). It is also possible to have an abnormal heartbeat (Healthwise,
2006). Other symptoms include blood or pus in the stool, dehydration, and weight loss (Mayo Clinic,
2006). Watery diarrhea is the most common symptom of CDAD in children (Infectious Diseases and
Immunization Committee, 2000). Rarely are symptoms manifested outside the gastrointestinal tract, but
can include cellulitis, bacteremia, visceral abscess formation, and reactive arthritis. A common indicator
would be leukocytosis with a white blood cell count greater than 30.0 x109/L (Hull and Beck, 2004).
Symptoms can appear immediately after or during antimicrobial therapy, but can often appear
several weeks after completing all antibiotics. This was evidenced in a study of cancer outpatients
diagnosed with CDAD where the median interval (range 2-60 days) from discharge to infection was 20.3
days – a 3 week delay (Sunenshine and McDonald, 2006).
Range of disease can vary in different individuals from asymptomatic colonization to severe
fulminant pseudomembranous colitis.
Many cases are mild. Such patients develop mild to moderate watery diarrhea with abdominal
cramping and nausea, similar to ordinary viral gastroenteritis. They may last a short duration to several
weeks but usually improve without treatment (EMIS and PIP, 2007). Systemic symptoms are usually

Figure 6 –
Pathogenesis of
Clostridium difficile
Infection (Adapted
from “Clostridium
difficile –Associated
Diarrhea”, Schroeder,
2005)
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absent and disease would only be considered due to abdominal tenderness upon physical examination
(Sunenshine and McDonald, 2006). They may also include low grade leukocytosis and tenesmus – a
sudden urge to evacuate the rectum (Hull and Beck, 2004).
Moderate infectious symptoms include leukemoid reaction – a stress response to disease with
an increased leukocyte count of approximately 50.0 x109/L, fever, dehydration, nausea, vomiting, and
abdominal tenderness. Hull and Beck, 2004).
The severest cases present with dehydration and electrolyte disturbance, severe bloody
diarrhea, fever, and abdominal pain and cramping (EMIS and PIP, 2007). It may lead to sepsis and shock,
acidosis (increased acidity of blood plasma), tachycardia, multisystem organ failure including kidney
failure (due to rapid dehydration), hypoalbuminemia, paralytic ileus, ascites (fluid accumulation in the
peritoneal cavity), acute abdomen – colonic perforation, toxic megacolon (toxic colitis with dilatation),
and death. Endoscopic evaluation of the colon will show pseudomembraneous white patches or lesions

Figure 7 – (L) Image of normal cecum
(R) Image of pseudomembranes formed from Clostridium difficile overgrowth of
cecum.
(Adapted from Johnson, Medical Microbiology, 2009)
with erythema and edema. The lesions are yellow plaques 2-10 mm in diameter with interposed normal
intestinal mucosa (Hull and Beck, 2004). Should a patient develop paralytic ileus or toxic megacolon, it
may actually lead to a decrease in diarrheal episodes. (Sunenshine and McDonald, 2006). Toxic
megacolon is rare but has been documented in several cases, leading to a mortality rate of 33% for
those who develop it. A critical factor in survival would be early diagnosis of Clostridium difficileassociated pseudomembranous colitis (Cone and Wetzel, 1982).
Diagnosis
Detailed history is the first step to proper diagnosis. Patients are screened for recent antibiotic
usage, abdominal pain, diarrhea, and related symptoms. Doctors may still test without presence of
diarrhea since in rare instances C. difficile bacteria can cause abdominal pain and tenderness without
diarrhea (MedicineNet, 2008). C. difficile is also suspected when diarrhea develops during or soon after
hospitalization (EMIS and PIP, 2007).
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Treating without diagnostic laboratory basis is not indicated, especially since only 30% of
hospitalized patients with diarrhea have CDAD, even during epidemics. There are some exceptions for
which empiric therapy would be necessary – including severely ill or rapidly deteriorating high-risk
patients (Sunenshine and McDonald, 2006).
Patients with CDAD often have leukocytosis with strong elevation in severe enterocolitis.
Physicians may screen leukocyte count as well as for white blood cell presence in the stool.
Confirmation of those two tests proves positive for colitis and would need more testing to diagnose
CDAD (MedicineNet, 2008). Stool leukocyte measurement may have limited diagnostic accuracy
(Nation Master Encyclopedia, 2005). A sudden rise in the leukocyte count to between 30-50x109/L cells
combined with severe bandemia (immature white blood cells) is an indicator of fulminant colitis.
Patients should be monitored for leukemoid reaction as shock can progress very quickly (Schroeder,
2005).
Stool assay for Clostridium difficile is a routine method. It is not always reliable as it sometimes
produces false-negatives (Mayo Clinic, 2006). Additionally, although the most sensitive test possible, it
can also cause false-positives due to the available nontoxigenic strains. It must grow 48-96 hours anaerobically
for proper results. (Centers for Disease Control and
Prevention (CDC), 2005). It has an overall sensitivity of
95% but has a low specificity, necessitating toxicity
testing (Canadian Paediatric Society, Paediatrics & Child
Health, 2000). It is not specific for pathogenic toxinproducing strains of Clostridium difficile and is not as
clinically helpful (Schroeder, American Family Physician,
2005). It is the least chosen method of testing in
hospitals due to cost and length of procedure. It does
Figure 8 – anaerobic culture of
however have an advantage of lending itself to molecular
Clostridium difficile bacteria on
typing of strains, useful in a C. difficile outbreak
Cycloserin-Cefoxitin Fructose Agar
(Anaerobe Systems, CA)
(Sunenshine and McDonald, 2006).
(Adapted from Johnson, Medical
Antigen detection for C. difficile are rapid tests
Microbiology,
2009)
completed in less than an hour, used to detect presence of C. difficile antigen by latex agglutination or
immunochromatographicassays. It must be combined with toxin testing for diagnostic confirmation
(Centers for Disease Control and Prevention (CDC), 2005).
Toxin testing includes both enzyme immunoassay and tissue culture cytotoxicity.
Enzyme immunoassay detects toxins A, B, or both together. It uses monoclonal antibodies to
detect toxin (Hull and Beck, 2004). Assay is completed same-day but is less sensitive than tissue culture
cytotoxicity assay (Centers for Disease Control and Prevention (CDC), 2005). Enzyme-linked
Immunoabsorbant Assay (ELISA) has a sensitivity rate of 63-99% and a specificity of 93-100%. Experts
recommend sending as many as 3 samples to rule out disease if patients receive negative result, but
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may not be necessary as much with ELISA (Nation Master Encyclopedia, 2005).
The majority of
combination enzyme immunoassays have a sensitivity of 85-95%. It should not be used as an indicator
of response to therapy since results remain positive for extended duration in 25% of successfully treated
patients (Schroeder, 2005).
Tissue culture cytotoxicity tests only for presence of toxin B. It is called the ‘gold standard’ toxin
bioassay (Canadian Paediatric Society, Paediatrics & Child Health, 2000). It requires 24-48 hours for a
final result and is very sensitive for C. difficile (Centers for Disease Control and Prevention (CDC), 2005).
Organisms are cultured on selective medium and tested for toxin production and cytopathic effect in cell
culture. It is the most sensitive and specific test although it is slow and labor-intensive (Nation Master
Encyclopedia, 2005). Due to its high specificity and sensitivity, one should be cautious for false results
(Canadian Paediatric Society, 2000).
C. difficile toxin is very unstable. Toxin degrades at room temperature and may not be
detectable 2 hours after collection of stool. False-negative results are prevalent due to delayed testing
or lack of refrigeration.
Stool lactoferrin levels can also be a diagnostic test but has limited diagnostic accuracy as well
(Nation Master Encyclopedia, 2005). Other rapid testing such as Immunocard (Meridian Diagnostics) is
highly specific but has poor sensitivity with up to 20% false negative results (Canadian Paediatric Society,
2000). Latex agglutination-based assays recognize enzyme glutamate dehydrogenase but do not have
sensitivity (Hull and Beck, 2004). Polymerase chain reaction (PCR) detects toxigenic C. difficile.
Amplification of a gene portion of either toxin A, toxin B, or a combination of the two genes is
performed. PCR can be conducted on the specimen organisms for presence of toxins that match with
the reading of the known toxins. One testing conducted (Kato et al) amplified only toxin A from C.
difficile. Others had similar or less success. It is not as sensitive as other testing methods (Gerding et al,
1995).
Colon examination is used to confirm diagnosis of Clostridium difficile. Patients undergo
sigmoidoscopy or colonoscopy to screen for presence
of inflammation and pseudomembrane appearance,
both suggesting CDAD (Mayo Clinic, 2006). It should,
however, be reserved for when a patient’s condition
needs rapid diagnosis, to rule out other diagnoses, or
when clinical suspicion is high despite negative
results.
Colonoscopy can detect more than a
sigmoidoscopy since it examines the whole colon
where C. difficile can encompass, rather than just the
sigmoid colon (Hull and Beck, 2004).
Imaging tests such as CT scans provide
detailed images of the colon. Scans can show
thickening of the colon wall, common in
21

pseudomembranous colitis (Mayo Clinic, 2006). In conjunction with the clinical history, presence of
ascites, colon wall thickening, or dilation can predict severity of enterocolitis (Schroeder, 2005).
Treatment
No treatment is necessary for colonization without symptomology.
present with diagnosis confirmed, there are different treatment options.

Should symptoms be

If at all possible, the disease-causing antibiotics should be stopped. This alone can allow normal
intestinal flora to regenerate. Overgrowth of C. difficile would be reduced with less symptoms ensuing.
For mild to moderate diarrhea and other symptoms, cessation of antimicrobial therapy may be the only
necessary cause of treatment (EMIS and PIP, 2007). CDAD typically resolves in 23% of cases upon
removal from the antimicrobial treatment (Centers for Disease Control and Prevention (CDC), 2005).
Fluids may be given to prevent dehydration and restore electrolyte balance in the blood
(Healthwise, 2006).
For severe cases of diarrhea or diagnosed colitis, patients will be treated with an antibiotic that
eradicates C. difficile organisms, usually Vancomycin (Vancocin) or Metranidazole (Flagyl), for ten days.
In a study of 189 patients with CDAD, 97% responded to initial antibiotic therapy (Sunenshine and
McDonald, Cleveland Clinic Journal of Medicine, 2006). Symptoms should subside within 2-3 days. The
antibiotics can also prevent perforation of the colon if treated in time (EMIS and PIP, 2007). Drugs are
usually effective with few side effects (Centers for Disease Control and Prevention (CDC), 2007). In
severe cases, intravenous medications may need to be administered (Robert Michael Educational
Institute, 2007). Both Vancomycin and Metranidazole are equally effective. Physicians may choose to
prescribe Metranidazole first since it is far less expensive than Vancomycin. Vancomycin is reserved for
patients who are allergic to Metronidazole, do not respond to it, or have side effects. Other physicians
choose Vancomycin primarily for severe colitis since it can achieve higher antibiotic levels in the colon
and can theoretically be more effective at eradicating bacteria there with more area specificity
(MedicineNet, 2008).
It can, however, contribute to the growth of antibiotic-resistant bacteria.
Metranidazole can not be used for women who are pregnant or breastfeeding. Both antibiotics kill only
the active infectious form of C. difficile, not the tougher spores. Since spores are resistant and remain in
the body, infection can return, requiring further treatment (Mayo Clinic, 2006). For those unable to
tolerate oral medication, IV Metronidazole is used since it is excreted in the intestine (Canadian
Paediatric Society, 2000).
Other drug regimens compared in randomized therapeutic trials for CDAD with good results are
Bacitracin, Teicoplanin, and Colestipol. Cure rates in Bacitracin are somewhat lower than Vancomycin,
and it should be treated as a secondary agent in treatment. Colestipol is even lower than Bacitracin
(Gerding et al, 1995).
Some physicians prescribe supplementary probiotics to restore normal intestinal flora. A
natural yeast, Saccharomyces boulardii, and Lactobacillus species has proven effective in treating C.
difficile infections together with antibiotic (Sunenshine and McDonald, 2006).
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Antidiarrheal medications such as loperamide, diphenoxylate, and bismuth compounds are
contraindicated and can worsen the course of pseudomembranous colitis. Slowing of fecal transit tie
can possibly extend toxin-associated damage. Cholestyramine, usually used to lower cholesterol, is
more effective in slowing bowel motility without causing more damage (Nation Master Encyclopedia,
2005).
If the disease causes fulminant colitis, surgical resection of the colon may be needed, especially
with colon perforation (EMIS and PIP, 2007).
In e cases causing severe pain, organ failure, or
inflammation of abdominal wall lining, surgical removal may be the only option (Mayo Clinic, 2006).
Surgery should be considered especially if initial treatment does not resolve the disease and symptoms
progress rapidly. Still, treatment should not be considered failure before 6-7 days of therapy
(Sunenshine and McDonald, 2006). At times, a patient may relapse with recurring episodes of CDAD.
Multiple courses of antibiotics may be needed. Probiotic treatment may be helpful for this (Canadian
Paediatric Society, 2000). Approximately 15-35% of patients have recurrent disease. This could be from
reinfection or germination from residual spores. The most likely reason for relapse is that C. difficile had
not been completely eradicated during treatment (MedicineNet, 2008).
There is no evidence that
recurring infections cause more severe disease (Hull and Beck, College of Family Physicians of Canada,
2004). Another possible reason leading to relapse is the body’s inadequate production of antibodies
against the bacterial toxins (MedicineNet, 2008). Fecal enemas, however, are difficult to perform and
there is an increased risk of transmitting retroviruses or other infectious diseases (Schroeder, 2005).
Fecal bacteriotherapy, sometimes commonly called a “stool transplant”, has its basis in
probiotic therapy research. Normal intestinal bacterial flora obtained from the feces of a healthy
individual is infused through the intestine of the patient in an effort to restore normal flora balance,
decreasing the strength of the C. difficile organisms and lessen likelihood of recurrence. This treatment
is usually used for people with recurring episodes of disease. It has a success rate of nearly 95% (Nation

Figure 10 – Laboratory preparation of stool for fecal bacteriotherapy
(The Medical Post, 2009)
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Master Encyclopedia, 2005). Anaerobic bacteria and fecal rectal enemas are usually obtained from
healthy relatives to promote better acceptance by the patient’s body. They are instilled rectally and can
restore colonic flora (Hull and Beck, 2004).
For patients with multiple relapses possibly due to antibody deficiency, passive immunizations
with human gammaglobulin can be administered intravenously. This will grant them large amounts of
antibodies to eradicate the disease. Additional work is in progress to promote active vaccination against
C. difficile toxins, to increase patient levels of antibodies. (MedicineNet, 2008)

Prevention
Most importantly, avoid using antibiotics unless absolutely necessary. Antibiotics will not
eradicate viral illnesses, yet they are still used for that purpose several times annually. Even some
common bacterial ailments like bronchitis and ear infections can be treated without antibiotics (Mayo
Clinic, 2006). In particular, restriction of Clindamycin has been shown to decrease incident of CDAD
(Schroeder, 2005).
If antibiotics are necessary, have the physician prescribe from a narrow-spectrum range to be
taken in the shortest amount of time possible for least likelihood of disrupting intestinal flora (Mayo
Clinic, 2006).
Use probiotic supplements – yogurt with live cultures, acidophilus, and similar during the
antibiotic course. However, only Saccharomyces boulardii is proven effective against C. difficile
specifically (Mayo Clinic, 2006). Lactobacilli have been proven effective against antibiotic-associated
diarrhea, but not necessarily that caused by Clostridium difficile.
Any patient with CDAD, even asymptomatically colonized, can transmit the disease to others.
Only those on antibiotics, hospitalized, or with other prevailing risk factors are most likely to get ill. To
reduce transmission, wash hands carefully especially after restroom use and before eating. Regularly
clean surfaces used routinely, such as kitchens and bathrooms (Centers for Disease Control and
Prevention (CDC), 2007). Ideally, a mixture of bleach and water should be used – with a ratio of 1:10
bleach to water. Patients with diarrhea should try to avoid using the same toilet other family members
use unless it can be washed out each time with the bleach and water mixture (Robert Michael 2007).
Hospitalized patients known or suspected to have the disease should be treated using the 1994
Hospital Infection Control Practices Advisory Committee (HICPAC) Guideline for Isolation Precautions in
Hospitals recommended contact precautions (Sunenshine and McDonald, Cleveland Clinic Journal of
Medicine, 2006). Place those patients in private rooms if possible, or with other patients with C. difficileassociated disease. Use gloves and gowns to prevent transmission and wash hands with alcohol-based
hand rubs or soap and water. Soap and water alone is best for direct care of CDAD patients as it is more
effective against spore-forming bacteria. Dedicate equipment to them wherever possible. (Division of
Healthcare Quality Promotion (DHQP), 2005) Visitors should wash hands with soap and warm water
24

before entering and leaving a CDAD patient’s room. (Mayo Clinic, 2006). One hospital reported a 60%
decrease in CDAD after instituting more stringent precautions (Sunenshine and McDonald, 2006).

Summary
Clostridium difficile-Associated Disease (CDAD) may be a slightly rare disease but with
devastating effects. Due to depletion of normal intestinal flora in conjunction with other risk factors
including immunocompromised state or recent hospitalization, dormant resistant spores transform to
virulent possibly toxigenic infectious form of bacteria that can multiply rapidly. Although broad in
arrange of symptomology, the possibility of leading to severe pseudomembranous colitis with risk of
colonic perforation, toxic megacolon, or death exists. Treatment is possible – with expensive drugs and
other measures, but not without the possibility of relapse, even numerous reoccurrences. Prevention
must be taken to avoid susceptibility to this virulent and damaging organism altogether, by maintaining
proper precautions. Should someone already have the disease, proper care must be implemented to
ensure no further transmission as spores can be spread through contact and fecal-oral methods.
Research is still preliminary for other treatments, including vaccination against C. difficile toxins. With
proper prevention and treatment, and increase in patient antibodies to target the organism, even in the
absence of normal intestinal flora, Clostridium difficile-Associated Disease can be eradicated.
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